LifeScan Announces Transformational Partnership with I-SENS to Launch OneTouch® Continuous Glucose Monitoring System

Why It Matters

The deal propels LifeScan into the high‑growth CGM market, enhancing its competitive stance and expanding access to real‑time glucose data for European patients.

Key Takeaways

• LifeScan partners with i‑SENS for CGM launch
• OneTouch® Vita CGM debut in four European countries 2027
• Leverages i‑SENS biosensor tech and LifeScan distribution
• Expands LifeScan beyond traditional blood glucose meters
• Addresses growing European CGM demand

Pulse Analysis

The continuous glucose monitoring (CGM) sector has surged in the past decade, driven by demand for real‑time data and tighter glycemic control. Global CGM sales are projected to exceed $10 billion by 2028, with Europe accounting for a sizable share. LifeScan, a veteran in finger‑stick glucose meters and digital health, has relied on its OneTouch® brand for more than 40 years. By entering the CGM space, the company seeks to capture a slice of this rapidly expanding market and modernize its product portfolio.

The partnership with i‑SENS combines two complementary strengths: i‑SENS’s advanced biosensor and electrochemical expertise, and LifeScan’s extensive distribution network and trusted brand equity. Together they will introduce the OneTouch® Vita CGM system in Germany, Ireland, Portugal, and Belgium by early 2027, with a roadmap for additional European rollouts. The device is expected to offer factory‑calibrated accuracy, seamless integration with existing OneTouch digital platforms, and a user‑friendly sensor design that aligns with i‑SENS’s reputation for intuitive products.

Strategically, the move positions LifeScan against incumbents such as Abbott’s FreeStyle Libre and Dexcom’s G6, intensifying competition on price, data connectivity, and customer support. For patients, the expanded availability of CGM technology promises earlier detection of glucose excursions and reduced finger‑stick burden. Moreover, the collaboration signals a broader trend of legacy glucose‑meter manufacturers partnering with biosensor innovators to accelerate time‑to‑market. As regulatory pathways streamline and reimbursement improves across Europe, LifeScan’s CGM entry could accelerate its revenue diversification and reinforce its standing in digital diabetes care.